Sanofi announced on December 15th that the targeted drug for the treatment of chronic graft-versus-host disease (CGVHD), Besudil Mesylate Tablets (REZUROCK), is marketed under the Chinese name of Yilaike; Reg; It has been officially approved, which further accelerates the commercial launch of Sanofi in China and improves the accessibility of medication for patients. Yilai Ke& Reg; It is a targeted ROCK2 inhibitor for the treatment of CGVHD, used to treat CGVHD patients aged 12 years and above who have insufficient response to glucocorticoids or other systemic therapies.